Novartis | NVS - Ebitda


Novartis reported $5.41B in EBITDA for its fiscal quarter ending in March of 2026.





Ebitda Change Date
AbbVie USD 5.37B 1.85B Dec/2025
Amgen USD 5.14B 775M Dec/2025
AstraZeneca USD 5.67B 1.29B Mar/2026
Bausch Health Companies USD 837M 94M Mar/2026
Biogen USD 649.7M 76.5M Mar/2026
Bristol-Myers Squibb USD 2.88B 1.36B Dec/2025
Canopy Growth CAD -137M 134.13M Mar/2026
Corcept Therapeutics USD 4.2M 6.5M Dec/2025
Drreddys Laboratories INR 8.63B 12.96B Mar/2026
Eli Lilly USD 12.14B 4.26B Dec/2025
Gilead Sciences USD 3.02B 1.01B Dec/2025
GlaxoSmithKline GBP 2.77B 1.65B Mar/2026
Glaxosmithkline GBP 2.77B 1.98B Mar/2026
J&J USD 8.27B 1.08B Mar/2026
Merck USD 6.3B 2.09B Dec/2025
Novartis USD 5.3B 530M Mar/2026
Novartis USD 5.41B 431M Mar/2026
Pacira USD 40.24M 1.53M Mar/2026
Perrigo USD 141.6M 1.34B Mar/2026
Pfizer USD 5.99B 5.23B Mar/2026
Phibro Animal Health USD 68.1M 6.2M Dec/2025
Prestige Brands USD 90.82M 3.99M Dec/2025
Roche Holding CHF 12.68B 2.36B Jun/2024
Sanofi EUR 3.31B 3.65B Mar/2026
Sanofi EUR 2.72B 2.94B Mar/2026
Supernus Pharmaceuticals USD 29.23M 19.27M Mar/2026
Zoetis USD 939M 101M Dec/2025